NO328863B1 - Farmasoytisk preparat for oral administrering inneholdende omeprazol - Google Patents
Farmasoytisk preparat for oral administrering inneholdende omeprazol Download PDFInfo
- Publication number
- NO328863B1 NO328863B1 NO20014074A NO20014074A NO328863B1 NO 328863 B1 NO328863 B1 NO 328863B1 NO 20014074 A NO20014074 A NO 20014074A NO 20014074 A NO20014074 A NO 20014074A NO 328863 B1 NO328863 B1 NO 328863B1
- Authority
- NO
- Norway
- Prior art keywords
- preparation according
- weight
- percent
- liquid carrier
- fatty acids
- Prior art date
Links
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 title claims description 22
- 229960000381 omeprazole Drugs 0.000 title claims description 22
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 4
- 238000002360 preparation method Methods 0.000 claims description 25
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 16
- 230000002209 hydrophobic effect Effects 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 13
- 150000004667 medium chain fatty acids Chemical class 0.000 claims description 11
- 239000002562 thickening agent Substances 0.000 claims description 11
- 239000002610 basifying agent Substances 0.000 claims description 8
- -1 propylene glycol diesters Chemical class 0.000 claims description 8
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 8
- 239000008158 vegetable oil Substances 0.000 claims description 8
- 239000008159 sesame oil Substances 0.000 claims description 7
- 235000011803 sesame oil Nutrition 0.000 claims description 7
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 5
- 239000004359 castor oil Substances 0.000 claims description 5
- 235000019438 castor oil Nutrition 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 5
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims description 5
- 239000004302 potassium sorbate Substances 0.000 claims description 5
- 229940069338 potassium sorbate Drugs 0.000 claims description 5
- 235000010241 potassium sorbate Nutrition 0.000 claims description 5
- 150000003626 triacylglycerols Chemical class 0.000 claims description 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 4
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- PHMQYKDOTWAOBI-UHFFFAOYSA-N decanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCC(O)=O PHMQYKDOTWAOBI-UHFFFAOYSA-N 0.000 claims description 3
- 239000000203 mixture Substances 0.000 description 15
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 210000000936 intestine Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012051 hydrophobic carrier Substances 0.000 description 3
- 229940126409 proton pump inhibitor Drugs 0.000 description 3
- 239000000612 proton pump inhibitor Substances 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 1
- FZTHHIGKHFQAKY-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl decanoate Chemical compound CCCCCCCCCC(=O)OC(C)COC(=O)CCCCCCC FZTHHIGKHFQAKY-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 150000001734 carboxylic acid salts Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- YZWQUQVFVLJWCS-UHFFFAOYSA-N decanoic acid;octanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O YZWQUQVFVLJWCS-UHFFFAOYSA-N 0.000 description 1
- PWEOPMBMTXREGV-UHFFFAOYSA-N decanoic acid;octanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCC(O)=O.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O.CCCCCCCCCC(O)=O PWEOPMBMTXREGV-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940041667 oral paste Drugs 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12125399P | 1999-02-23 | 1999-02-23 | |
| PCT/US2000/004170 WO2000050038A1 (en) | 1999-02-23 | 2000-02-18 | Pharmaceutical composition containing proton pump inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20014074L NO20014074L (no) | 2001-08-22 |
| NO20014074D0 NO20014074D0 (no) | 2001-08-22 |
| NO328863B1 true NO328863B1 (no) | 2010-05-31 |
Family
ID=22395498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20014074A NO328863B1 (no) | 1999-02-23 | 2001-08-22 | Farmasoytisk preparat for oral administrering inneholdende omeprazol |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US6316481B1 (xx) |
| EP (1) | EP1156806B1 (xx) |
| JP (1) | JP2002537337A (xx) |
| KR (1) | KR100701448B1 (xx) |
| CN (1) | CN1227009C (xx) |
| AR (1) | AR029615A1 (xx) |
| AT (1) | ATE263562T1 (xx) |
| AU (1) | AU771061B2 (xx) |
| BG (1) | BG65291B1 (xx) |
| BR (1) | BR0008403A (xx) |
| CA (1) | CA2362932C (xx) |
| CO (1) | CO5140102A1 (xx) |
| CZ (1) | CZ301647B6 (xx) |
| DE (1) | DE60009675T2 (xx) |
| DK (1) | DK1156806T3 (xx) |
| EA (1) | EA004683B1 (xx) |
| ES (1) | ES2216870T3 (xx) |
| HK (1) | HK1041650A1 (xx) |
| HR (1) | HRP20010615B1 (xx) |
| HU (1) | HU228181B1 (xx) |
| IL (1) | IL144131A0 (xx) |
| ME (1) | ME00864B (xx) |
| NO (1) | NO328863B1 (xx) |
| NZ (1) | NZ512771A (xx) |
| PL (1) | PL195783B1 (xx) |
| PT (1) | PT1156806E (xx) |
| RS (1) | RS50023B (xx) |
| SK (1) | SK286371B6 (xx) |
| TW (1) | TW587936B (xx) |
| WO (1) | WO2000050038A1 (xx) |
| ZA (1) | ZA200106104B (xx) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| US6852739B1 (en) | 1999-02-26 | 2005-02-08 | Nitromed Inc. | Methods using proton pump inhibitors and nitric oxide donors |
| ES2345873T3 (es) * | 2000-05-30 | 2010-10-05 | Merial Limited | Composiciones para la prevencion de ulceras en caballos. |
| KR20030059318A (ko) | 2000-12-07 | 2003-07-07 | 알타나 파마 아게 | 산 불안정성 활성 성분을 포함하는 현탁액 형태의 약학 제제 |
| AU2002231654A1 (en) | 2000-12-07 | 2002-06-18 | Byk Gulden Lomberg Chemische Fabrik G.M.B.H. | Pharmaceutical paste comprising an acid-labile active ingredient |
| DE10061135C1 (de) * | 2000-12-07 | 2002-11-07 | Byk Gulden Lomberg Chem Fab | Pharmazeutische Zubereitung in Form einer Paste enthaltend einen säurelabilen Wirkstoff |
| CA2493618A1 (en) | 2002-08-01 | 2004-02-12 | Nitromed, Inc. | Nitrosated proton pump inhibitors, compositions and methods of use |
| GB2394895A (en) * | 2002-11-06 | 2004-05-12 | Cipla Ltd | Proton pump inhibitor composition in paste form |
| WO2005000269A1 (en) * | 2003-06-26 | 2005-01-06 | Cipla Limited | Pharmaceutical formulations comprising a proton pump inhibitor |
| US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| WO2006026829A1 (en) * | 2004-09-09 | 2006-03-16 | Metelli Pty Ltd | Stable paste composition of enteric coated acid labile active agent and use thereof |
| CN101500553B (zh) * | 2006-07-25 | 2012-04-18 | 维克塔有限公司 | 联合使用小分子二羧酸的衍生物与ppi用于抑制胃酸分泌的组合物和方法 |
| CN101610754A (zh) | 2007-02-16 | 2009-12-23 | Aska制药株式会社 | 含有微粒油性混悬液的药物组合物 |
| US8530500B2 (en) | 2009-07-20 | 2013-09-10 | Vetegen, Llc | Stable pharmaceutical omeprazole formulation for oral administration |
| WO2012106058A2 (en) | 2011-01-31 | 2012-08-09 | New Market Pharmaceuticals | Animal treatments |
| US10064849B2 (en) | 2012-05-02 | 2018-09-04 | New Market Pharmaceuticals | Pharmaceutical compositions for direct systemic introduction |
| EP3791866A1 (en) | 2012-05-02 | 2021-03-17 | NewMarket Pharmaceuticals LLC | Pharmaceutical compositions for direct systemic introduction |
| GB2524351B (en) * | 2013-10-18 | 2016-12-14 | Norbrook Lab Ltd | Proton Pump Inhibitor Paste Compositions |
| ES2717029T3 (es) * | 2013-10-18 | 2019-06-18 | Norbrook Lab Ltd | Composiciones de pasta inhibidora de la bomba de protones |
| DK3386507T3 (da) | 2015-12-08 | 2023-09-18 | Luoda Pharma Ltd | Metoder og sammensætninger til behandling af mavesår |
| WO2017145146A1 (en) | 2016-02-25 | 2017-08-31 | Dexcel Pharma Technologies Ltd. | Compositions comprising proton pump inhibitors |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| US10137111B2 (en) | 2016-08-11 | 2018-11-27 | Adamis Pharmaceuticals Corporation | Drug compositions comprising an anti-parasitic and proton pump inhibitor |
| EP3720844A4 (en) | 2017-12-08 | 2021-08-11 | Adamis Pharmaceuticals Corporation | MEDICINAL COMPOSITIONS |
| ES2723873B1 (es) * | 2018-03-01 | 2020-05-13 | Hernan Ma Carmen Batanero | Medicamento combinado con omeprazol y vitamina B12 |
| CN112972481A (zh) * | 2021-03-18 | 2021-06-18 | 华农（肇庆）生物产业技术研究院有限公司 | 药物组合物及其制备方法和应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4255432A (en) | 1979-09-06 | 1981-03-10 | Syntex (U.S.A.) Inc. | 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof |
| DK130287D0 (da) | 1987-03-13 | 1987-03-13 | Benzon As Alfred | Oralt praeparat |
| SE9301489D0 (sv) | 1993-04-30 | 1993-04-30 | Ab Astra | Veterinary composition |
| US5708017A (en) * | 1995-04-04 | 1998-01-13 | Merck & Co., Inc. | Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors |
-
2000
- 2000-02-18 JP JP2000600649A patent/JP2002537337A/ja active Pending
- 2000-02-18 AU AU33687/00A patent/AU771061B2/en not_active Expired
- 2000-02-18 EA EA200100905A patent/EA004683B1/ru not_active IP Right Cessation
- 2000-02-18 DK DK00911862T patent/DK1156806T3/da active
- 2000-02-18 AT AT00911862T patent/ATE263562T1/de active
- 2000-02-18 ME MEP-2001-504A patent/ME00864B/me unknown
- 2000-02-18 HU HU0200325A patent/HU228181B1/hu unknown
- 2000-02-18 BR BR0008403-4A patent/BR0008403A/pt not_active Application Discontinuation
- 2000-02-18 ES ES00911862T patent/ES2216870T3/es not_active Expired - Lifetime
- 2000-02-18 CA CA2362932A patent/CA2362932C/en not_active Expired - Lifetime
- 2000-02-18 DE DE60009675T patent/DE60009675T2/de not_active Expired - Lifetime
- 2000-02-18 NZ NZ512771A patent/NZ512771A/xx not_active IP Right Cessation
- 2000-02-18 WO PCT/US2000/004170 patent/WO2000050038A1/en active IP Right Grant
- 2000-02-18 PT PT00911862T patent/PT1156806E/pt unknown
- 2000-02-18 EP EP00911862A patent/EP1156806B1/en not_active Expired - Lifetime
- 2000-02-18 CZ CZ20013058A patent/CZ301647B6/cs not_active IP Right Cessation
- 2000-02-18 SK SK1206-2001A patent/SK286371B6/sk not_active IP Right Cessation
- 2000-02-18 KR KR1020017010623A patent/KR100701448B1/ko active IP Right Grant
- 2000-02-18 IL IL14413100A patent/IL144131A0/xx not_active IP Right Cessation
- 2000-02-18 RS YUP-504/01A patent/RS50023B/sr unknown
- 2000-02-18 PL PL00350729A patent/PL195783B1/pl unknown
- 2000-02-18 CN CNB00804029XA patent/CN1227009C/zh not_active Expired - Lifetime
- 2000-02-22 TW TW089103033A patent/TW587936B/zh not_active IP Right Cessation
- 2000-02-22 AR ARP000100749A patent/AR029615A1/es active IP Right Grant
- 2000-02-22 US US09/510,312 patent/US6316481B1/en not_active Expired - Lifetime
- 2000-02-22 CO CO00012143A patent/CO5140102A1/es unknown
-
2001
- 2001-07-25 ZA ZA200106104A patent/ZA200106104B/xx unknown
- 2001-07-30 BG BG105754A patent/BG65291B1/bg unknown
- 2001-08-22 NO NO20014074A patent/NO328863B1/no not_active IP Right Cessation
- 2001-08-23 HR HR20010615A patent/HRP20010615B1/xx not_active IP Right Cessation
-
2002
- 2002-05-07 HK HK02103435A patent/HK1041650A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO328863B1 (no) | Farmasoytisk preparat for oral administrering inneholdende omeprazol | |
| JP4603631B2 (ja) | プロトンポンプ阻害剤を含有する医薬組成物 | |
| FI96095C (fi) | Menetelmä jatkuvavapautteisen lääkevalmisteen valmistamiseksi | |
| WO2006026829A1 (en) | Stable paste composition of enteric coated acid labile active agent and use thereof | |
| GB2394895A (en) | Proton pump inhibitor composition in paste form | |
| MXPA01008525A (en) | Pharmaceutical composition containing proton pump inhibitors | |
| WO2005000269A1 (en) | Pharmaceutical formulations comprising a proton pump inhibitor | |
| AU2005100669A4 (en) | Enteric coated paste compositions and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |